Human intelligence enhanced by artificial intelligence
A revolution in cardiovascular identification and management
How are you reducing heart failure readmissions?
How are you managing your cardiovascular patient population?
How do you know if a structural heart patient has been missed?
How are you reducing heart failure readmissions?
How are you managing your cardiovascular patient population?
How do you know if a structural heart patient has been missed?
Human intelligence enhanced by artificial intelligence
A revolution in cardiovascular identification and management
The Solution 
Improving Outcomes
This leading-edge solution delivers actionable insights through intuitive digital-health platforms, proprietary A.I. powered analytics and deep clinical expertise to help leading systems elevate the standard of patient care.
The Challenge
Navigate an Ocean of Clinical Data
CardioCare integrates electronic health record (EHR) and echo data to help providers navigate the vast amount of patient data and find the right patients at the right time:
Closing Gaps
in Care
Help physicians identify eligible patients early to help prevent hospitalizations, stroke & death
Increasing Guideline-Directed Therapy
Increase appropriate referrals to cardiovascular (CV) specialists
Improving Visibility
& Catchment
Identify drivers of care variability in your health system
The Solution
Improving Outcomes
This leading-edge solution delivers actionable insights through intuitive digital-health platforms, proprietary A.I. powered analytics and deep clinical expertise to help leading systems elevate the standard of patient care.
guideline-directed care.
guideline-directed care.
guideline-directed care.
Identify patients eligible for clinical trials.
Identify patients eligible for clinical trials.
Identify patients eligible for clinical trials.
See where there are opportunities for education and outreach.
See where there are opportunities for education and outreach.
See where there are opportunities for education and outreach.
The CardioCare platform is not intended for use in the diagnosis, cure, mitigation, treatment or prevention of cardiovascular diseases.
Real Results
Our Approach Delivers Reproducible Results
Mean 25% increase
in SHD procedures1
Up to 21% increase
in HFrEF GDMT2
4x return on investment
in 12 months3
2.Data representative of 1 HF center of excellence teaching institution from 1/1/2020 – 11/30/2022.
3. Representative of 6 sites who have active physician engagement, are participating in digital day, and regularly using the CardioCare platform.
guideline-directed medical therapy, GDMT; heart failure with reduced ejection fraction, HFrEF; structural heart disease, SHD
Customers
Working with Top Cardiovascular Programs Across the U.S.
Don't just take our word for it. Talk to our team today to learn more about partnerships.
Presented or Published in
Testimonials
Leading hospitals partner with egnite’s CardioCare platform to reduce variability in care and improve guideline-directed therapy for patients with cardiovascular disease.
Gagnon Cardiovascular Institute, Morristown Medical Center
Resources
SGLT2i + GLP-1 RA: A Dynamic Duo in HFpEF?
Heart failure with a preserved ejection fraction (HFpEF) accounts for more than half of all heart failure cases and carries significant morbidity and mortality risk, especially after hospitalization1. Historically, management of the disease is largely focused on comorbidity management and lifestyle modifications, given that available therapies had not demonstrated sufficient impact on hospitalization burden or mortality. In recent years, however, the treatment paradigm for HFpEF has shifted, with a growing emphasis on SGLT2 inhibitors (SGLT2i). Originally developed to lower blood glucose levels in diabetic patients, several clinical trials have firmly established that SGLT2i is also beneficial for patients living with HFpEF2.
Two-Year Mortality Following Heart Failure Hospitalization in Patients with HFpEF Stratified by SGLT2i and GLP-1 RA Therapy: A Real-World Analysis
BACKGROUND Heart failure with a preserved ejection fraction (HFpEF) is characterized by frequent hospitalizations, and substantial mortality. While historically lacking effective therapies, newer treatments, including SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1 RA), have shown potential benefits. However, the clinical course of HFpEF under these therapies remains incompletely characterized, warranting further investigation. OBJECTIVES To […]
What the EARLY TAVR Trial Data Could Mean for Already Busy Heart Teams
On the heels of the exciting EARLY TAVR data and egnite’s Acute Valve Syndrome in Aortic Stenosis study, both led by Dr. Philippe Genereux, we’ve been asked by several cardiovascular (CV) administrators what a potential change in the management of asymptomatic severe aortic stenosis (SAS) patients could mean for their already busy heart teams.